May 27, 2020
BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine
Jan 22, 2020
BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
Jan 14, 2020
BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe
Dec 13, 2019
BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
Dec 05, 2019
BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer
Nov 26, 2019
BioLineRx to Host Investor and Analyst Breakfast Meeting on December 5, 2019 in New York
Nov 05, 2019
BioLineRx Presents Preclinical Data From Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic Tumor Growth and Favorable Changes in Tumor Microenvironment
Nov 05, 2019
BioLineRx Announces BL-8040 in Combination With KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients
Oct 31, 2019
BioLineRx to Present Two Posters at the Society for Immunotherapy of Cancer (SITC) 2019
Oct 29, 2019
BioLineRx to Deliver Oral Presentation at ESMO Immuno-Oncology Congress 2019
Sep 03, 2019
BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
Feb 12, 2019
Frost & Sullivan Publishes Immediate Report on BiolineRx
Feb 04, 2019
BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
Dec 11, 2018
BioLineRx Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology Collaboration
Dec 06, 2018
BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York
Nov 01, 2018
BioLineRx to Report Third Quarter 2018 Results on November 8, 2018
Oct 20, 2018
BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress
Oct 03, 2018
BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications
Jul 30, 2018
BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer
May 17, 2018
BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML Patients